Earth Science Tech Inc. (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, held its first Annual Meeting of Stockholders virtually on August 31, 2026. During the meeting, shareholders approved several key proposals aimed at advancing the company's uplisting strategy to a national exchange such as Nasdaq or NYSE.
Shareholders authorized the Board of Directors to pursue a reverse stock split if deemed necessary to meet the bid price requirements for an uplisting. This authorization is valid for a period of 12 months, giving the Board flexibility to act in the best interest of the company. Giorgio R. Saumat, CEO and Chairman of the Board, emphasized that he will not support a reverse split unless it is absolutely required for the uplisting.
In addition, stockholders authorized the Board's Independent Special Committee to negotiate the retirement of the Series B Preferred Stock. This move would eliminate the current dual-class voting structure, potentially simplifying the company's governance and making it more attractive to institutional investors. The retirement of the Series B Preferred Stock is seen as a critical step toward achieving a more conventional corporate structure that aligns with the standards of national exchanges.
Shareholders also ratified the appointment of Semple, Marchal & Cooper LLP as an independent registered public accounting firm, re-elected seven director nominees, and authorized a new non-dilutive executive compensation framework. The new compensation structure is designed to align executive interests with those of shareholders without diluting existing shares, which could be particularly appealing to investors concerned about share value.
These approvals mark a significant milestone for Earth Science Tech as it seeks to elevate its profile in the public markets. An uplisting to a national exchange like Nasdaq or NYSE could increase the company's visibility, improve liquidity, and attract a broader base of investors, including institutional funds that often have restrictions on investing in over-the-counter stocks. For shareholders, a successful uplisting could lead to greater market recognition and potentially a higher valuation.
The company's strategic focus on healthcare, pharmacy, and telemedicine positions it in a growing sector, and the governance changes approved by shareholders may enhance its ability to execute on its business plan. The retirement of the Series B Preferred Stock, in particular, could resolve potential conflicts of interest and streamline decision-making.
Investors and industry observers will be watching closely to see if the Board decides to implement the reverse stock split and how the company progresses toward its uplisting goals. The latest news and updates relating to ETST are available in the company's newsroom at https://ibn.fm/ETST.
For more information on the meeting and the proposals, shareholders can refer to the full details provided by the company at https://ibn.fm/HIqJ9.
